Bracco molecular imaging subsidiary Blue Earth Diagnostics is highlighting clinical results from a German study using PET/CT and its radiohybrid prostate-specific membrane antigen-targeted compound for prostate cancer.
Researchers from the Technical University of Munich presented study results at the American Urological Association's 2020 virtual meeting. A group led by Dr. Tobias Maurer found that F-18 PET/CT results using the compound, called rhPSMA-7.3, showed sensitivity of 81%, specificity of 88%, and diagnostic accuracy of 86% in 56 patients with intermediate or high-risk prostate cancer when compared with histopathological results.
These results have been included in Blue Earth's investigational new drug submission to the U.S. Food and Drug Administration.
